+44 1223 790975Chemotherapy: Open Access : Citations & Metrics Report
Articles published in Chemotherapy: Open Access have been cited by esteemed scholars and scientists all around the world. Chemotherapy: Open Access has got h-index 12, which means every article in Chemotherapy: Open Access has got 12 average citations.
Following are the list of articles that have cited the articles published in Chemotherapy: Open Access.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|
Year wise published articles |
30 | 8 | 0 | 17 | 24 | 52 |
Year wise citations received |
61 | 68 | 83 | 58 | 143 | 116 |
| Journal total citations count | 709 |
| Journal impact factor | 1.81 |
| Journal 5 years impact factor | 3.80 |
| Journal cite score | 4.89 |
| Journal h-index | 12 |
| Journal h-index since 2018 | 9 |
Important citations (402)
rahul j (2015) significance of angiogenesis in both survival and extermination (via treatment) of the tumour rrjmh 4: 1-14. |
|
pop f, iancu m, lisencu c (2016) psychological intervention throughout the cancer trajectory: a case report. cognitie, creier, comportament/cognition, brain, behavior 20: 225-237. |
|
Kumar pm, jebasingh jj (2015) physiological problems and quality of life of patients with breast cancer: a review. biomed pharmacol j 8:683-686. |
|
ventura f, koinberg i, karlsson p, sawatzky r, öhlén j (2016) purposeful agency in support seeking during cancer treatment from a person-centered perspective. global qualitative nursing research 3: 2333393616630672. |
|
Ventura f (2016) person-centred e-support. foundations for the development of nursing interventions in outpatient cancer care. |
|
Ventura f (2016) person-centred e-support. foundations for the development of nursing interventions in outpatient cancer care. |
|
Milanti a, metsälä e, hannula l (2016) reducing psychological distress in patients undergoing chemotherapy. br j nurs 25: s25-30. |
|
Tuncer g, yucel sc (2014) comfort and anxiety levels of women with early stage breast cancer who receive radiotherapy. asian pacific j cancer prevention 15: 2109-2114. |
|
Clara ja, sallman da, padron e (2016) clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes. cancer biol med 13:360. |
|
Clara ja, sallman da, padron e (2016) clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes. cancer biology & medicine 13:360. |
|
Gerds at (2014) i walk the other line: myelodysplastic/myeloproliferative neoplasm overlap syndromes. current hematologic malignancy reports.9: 400-6. |
|
tiu rv, sekeres ma (2014) making sense of the myelodysplastic/myeloproliferative neoplasms overlap syndromes. curr opin hematol 21: 131-40. |
|
Rahul j (2015) significance of angiogenesis in both survival and extermination (via treatment) of the tumour rrjmh 4: 1-14 |
|
Wagner vp (2016) novas modalidades terapêuticas para o carcinoma mucoepidermoide e seus efeitos na população de células tronco tumorais. |
|
Rahul j (2015) significance of angiogenesis in both survival and extermination (via treatment) of the tumour rrjmh 4: 1-14 |
|
Krushkal j, zhao y, hose c, monks a, doroshow jh, et al. (2016) concerted changes in transcriptional regulation of genes involved in dna methylation, demethylation, and folate-mediated one-carbon metabolism pathways in the nci-60 cancer cell line panel in response to cancer drug treatment. clinical epigenetics 8:73. |
|
Sanddhya ns, stalin r, sachdanandam p, malathi r, shanthi p (2017) in vitro evaluation of penta-o-galloyl-β-d-glucose (pgg) on mirna expression and apoptosis in bcr-abl+ all. gene reports 6: 26-31. |
|
Datta j, islam m, dutta s, roy s, pan q, (2016) suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor micrornas. oral oncology 56:32-39. |
|
Ye f, karn j (2015) bacterial short chain fatty acids push all the buttons needed to reactivate latent viruses. stem cell epigenetics 2. |
|
Lillico r, stesco n, khorshid amhad t, cortes c, namaka mp,et al. (2016) inhibitors of enzymes catalyzing modifications to histone lysine residues: structure, function and activity. future medicinal chemistry. 8: 879-897. |
|